Saturday 17 October 2026
Export XLO’s income statement to Excel — free account
Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $43.8 million, up 589.9% from fiscal 2024. In the quarter to June 2026, revenue grew 131.2%, EPS grew 85.3% and free cash flow fell 26.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
8.77
0.25
−2.77%
Follow XLO
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 119.35 | 27.30 | 6.86 | 7.00 | 8.61 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 391.30 | 228.76 | 68.88 | 27.02 | 23.80 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 74 | 89 | 73 | 64 | 76 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.10 | 0.58 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 6 | 44 | ||||
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | 100.00 | 100.00 | |||||
| EBT | — | — | — | (17) | (55) | (76) | (88) | (76) | (58) | (35) | |||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (918.05) | (80.05) | |||||
| Net income | — | 0 | — | (17) | (55) | (76) | (88) | (76) | (58) | (35) | |||||
| Depreciation | — | — | — | 0 | 1 | 1 | 2 | 2 | 2 | 2 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.66 | 5.24 | ||||
| Earnings | — | — | — | (0.63) | (1,476.51) | (189.36) | (45.10) | (38.94) | (15.27) | (4.19) | |||||
| Cash flow | — | — | — | (0.66) | (965.00) | (201.73) | (38.72) | (34.95) | (4.81) | (0.60) | |||||
| Capex | — | — | — | 0.00 | (58.50) | (2.75) | (0.95) | (0.25) | (0.01) | (0.06) | |||||
| Free cash flow | — | — | — | (0.66) | (1,023.50) | (204.47) | (39.67) | (35.20) | (4.82) | (0.66) | |||||
| Book value | — | — | — | 1.40 | (141.31) | 463.23 | 54.02 | 18.76 | 4.60 | 4.22 | |||||
| Shares, m | — | — | — | 27 | 0 | 0 | 2 | 2 | 4 | 8 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | 1.71 | |||||
| P/B | — | — | — | — | — | — | — | — | 2.90 | 2.12 | |||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | (1.40) | |||||
| EV/FCF | — | — | — | — | — | — | — | — | 0.14 | 11.09 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (18) | (36) | (81) | (76) | (69) | (18) | (5) | ||||
| Capex | — | — | — | (1) | (2) | (1) | (2) | 0 | 0 | (1) | |||||
| Free cash flow | — | — | — | (18) | (38) | (82) | (78) | (69) | (18) | (6) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 46 | (2) | 190 | 103 | 32 | 33 | 89 | ||||
| Total debt | — | — | — | 19 | 7 | 10 | 3 | — | — | — | |||||
| Net debt | — | — | — | (30) | (12) | (188) | (117) | (45) | (55) | (138) | |||||
| Shareholders’ equity | — | — | — | 39 | (5) | 185 | 106 | 37 | 18 | 35 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (55.20) | (111.51) | (59.60) | (49.39) | (76.37) | (88.24) | (31.04) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | 30.69 | 97.90 | (148.42) | (60.62) | (107.25) | (214.02) | (132.53) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Xilio Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| APLM Apollomics Inc. | $61.2M | — (loss-making) | — | — | 0.00% | +76.08% (above 0%: growing) | — | — | Compare |
| BMEA Biomea Fusion, Inc. | $60.6M | — (loss-making) | — | — | n/m | +47.80% (above 0%: growing) | 0.00% | 0.00% | Compare |
| PLRX Pliant Therapeutics, Inc. | $60.2M | — (loss-making) | — (loss-making) | −95.03% (below 0%: shrinking) | n/m | +68.61% (above 0%: growing) | 0.00% | 0.00% | Compare |
| XLO Xilio Therapeutics, Inc. | $59.4M | — (loss-making) | — (loss-making) | +131.22% (above 0%: growing) | n/m | −26.23% (below 0%: shrinking) | 100.00% | (18.68%) | |
| GANX Gain Therapeutics, Inc. | $58.1M | — (loss-making) | — (loss-making) | +27.78% (above 0%: growing) | n/m | +8.22% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CNTB Connect Biopharma Holdings Limited Sponsored ADR | $57.1M | — (loss-making) | — (loss-making) | +296.56% (above 0%: growing) | n/m | −23.48% (below 0%: shrinking) | 100.00% | (635.98%) | Compare |
| TENX Tenax Therapeutics, Inc. | $56.5M | — (loss-making) | — | −77.98% (below 0%: shrinking) | n/m | −125.93% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ALPS Alps Group Inc. | $56.4M | — (loss-making) | — | — | n/m | −26.48% (below 0%: shrinking) | — | 0.00% | Compare |
| ELOX Senesco Technologies Inc. | $55.3M | — (loss-making) | — | — | n/m | −144.34% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| Median of peers | $57.6M | — | — | −25.10% | — | −7.63% | 0.00% | 0.00% |
Xilio Therapeutics, Inc. (XLO) key facts
- Strength: Xilio Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $43.8 million, up 589.9% from fiscal 2024.
- Xilio Therapeutics, Inc. (XLO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, XLO traded at $8.77, a market capitalization of $59.4 million.
- Return on equity was −132.5% and debt-to-equity 0.00.
- Its Altman Z-score is −3.34 (distress zone) for fiscal 2025.
Xilio Therapeutics, Inc. (XLO) Latest News
No news at this impact. Lower the threshold for more.